A number of research firms have changed their ratings and price targets for Otonomy (NASDAQ: OTIC):

  • 9/1/2017 – Otonomy was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 8/31/2017 – Otonomy had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $15.00 price target on the stock, down previously from $45.00.
  • 8/31/2017 – Otonomy had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $9.00 price target on the stock, down previously from $55.00.
  • 8/30/2017 – Otonomy was downgraded by analysts at J P Morgan Chase & Co from an “overweight” rating to a “neutral” rating. They now have a $8.00 price target on the stock, down previously from $28.00.
  • 8/30/2017 – Otonomy was downgraded by analysts at Piper Jaffray Companies from an “overweight” rating to a “neutral” rating. They now have a $8.00 price target on the stock, down previously from $32.00.
  • 8/23/2017 – Otonomy had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $55.00 price target on the stock.
  • 8/18/2017 – Otonomy was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Otonomy, Inc. engages in developing and commercializing therapeutics to address unmet medical needs in the otology market. It develops therapeutics for treatment of inner and middle ear disorders. The Company’s product candidates under development includes AuriPro to treat pediatric patients with middle ear effusion; and OTO-104 for the treatment of patients with Ménière’s disease. Otonomy, Inc. is headquartered in San Diego, California. “
  • 8/15/2017 – Otonomy was upgraded by analysts at J P Morgan Chase & Co from a “neutral” rating to an “overweight” rating. They now have a $28.00 price target on the stock.
  • 8/11/2017 – Otonomy was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/18/2017 – Otonomy was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Otonomy, Inc. engages in developing and commercializing therapeutics to address unmet medical needs in the otology market. It develops therapeutics for treatment of inner and middle ear disorders. The Company’s product candidates under development includes AuriPro to treat pediatric patients with middle ear effusion; and OTO-104 for the treatment of patients with Ménière’s disease. Otonomy, Inc. is headquartered in San Diego, California. “

Otonomy, Inc. (OTIC) opened at 3.50 on Wednesday. The company’s market capitalization is $106.06 million. The stock’s 50 day moving average is $15.35 and its 200-day moving average is $14.70. Otonomy, Inc. has a 1-year low of $3.15 and a 1-year high of $21.15.

Otonomy (NASDAQ:OTIC) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.03. Otonomy had a negative net margin of 8,172.38% and a negative return on equity of 57.43%. The firm had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.43 million. During the same period in the prior year, the firm earned ($0.98) EPS. The firm’s revenue for the quarter was up 312.5% on a year-over-year basis. On average, analysts expect that Otonomy, Inc. will post ($3.23) earnings per share for the current fiscal year.

In related news, insider Eric J. Loumeau sold 3,522 shares of the company’s stock in a transaction that occurred on Monday, June 26th. The shares were sold at an average price of $18.59, for a total transaction of $65,473.98. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 12.70% of the stock is owned by corporate insiders.

Otonomy, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase.

Receive News & Stock Ratings for Otonomy Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy Inc and related stocks with our FREE daily email newsletter.